HIGHLIGHTS
- who: Tarek Zaidieh from the (UNIVERSITY) have published the paper: Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy, in the Journal: (JOURNAL)
- what: The aims of the ongoing research are to prove the therapeutic potential of targeting mitochondria via DLCs in treating cancer and to identify effective biomarkers (such as ROS and specific mtDNA variations) that can predict drug response. This study aimed to explore the interrelationship between various mitochondrial genetic abnormalities (mtDNA variations and mtDNAcn change), baseline intracellular ROS levels and sensitivity to ROS-stimulating drugs such as . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.